223 related articles for article (PubMed ID: 35482445)
21. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ceribelli M; Hou ZE; Kelly PN; Huang DW; Wright G; Ganapathi K; Evbuomwan MO; Pittaluga S; Shaffer AL; Marcucci G; Forman SJ; Xiao W; Guha R; Zhang X; Ferrer M; Chaperot L; Plumas J; Jaffe ES; Thomas CJ; Reizis B; Staudt LM
Cancer Cell; 2016 Nov; 30(5):764-778. PubMed ID: 27846392
[TBL] [Abstract][Full Text] [Related]
22. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
23. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Kim H; Kim H; Feng Y; Li Y; Tamiya H; Tocci S; Ronai ZA
Sci Transl Med; 2020 Jul; 12(551):. PubMed ID: 32641491
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional Landscape of CUT-Class Homeobox Genes in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Nagel S; Rand U; Pommerenke C; Meyer C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474011
[TBL] [Abstract][Full Text] [Related]
25. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.
Ceroi A; Masson D; Roggy A; Roumier C; Chagué C; Gauthier T; Philippe L; Lamarthée B; Angelot-Delettre F; Bonnefoy F; Perruche S; Biichle S; Preudhomme C; Macintyre E; Lagrost L; Garnache-Ottou F; Saas P
Blood; 2016 Dec; 128(23):2694-2707. PubMed ID: 27702801
[TBL] [Abstract][Full Text] [Related]
26. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
Emadali A; Hoghoughi N; Duley S; Hajmirza A; Verhoeyen E; Cosset FL; Bertrand P; Roumier C; Roggy A; Suchaud-Martin C; Chauvet M; Bertrand S; Hamaidia S; Rousseaux S; Josserand V; Charles J; Templier I; Maeda T; Bruder-Costa J; Chaperot L; Plumas J; Jacob MC; Bonnefoix T; Park S; Gressin R; Tensen CP; Mecucci C; Macintyre E; Leroux D; Brambilla E; Nguyen-Khac F; Luquet I; Penther D; Bastard C; Jardin F; Lefebvre C; Garnache F; Callanan MB
Blood; 2016 Jun; 127(24):3040-53. PubMed ID: 27060168
[TBL] [Abstract][Full Text] [Related]
27. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
[TBL] [Abstract][Full Text] [Related]
28. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
30. Multiple Genomic Alterations, Including a Novel
Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475
[TBL] [Abstract][Full Text] [Related]
31. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
32. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
33. Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.
Pemmaraju N; Utengen A; Gupta V; Thompson MA; Lane AA
Curr Hematol Malig Rep; 2017 Dec; 12(6):592-597. PubMed ID: 29064025
[TBL] [Abstract][Full Text] [Related]
34. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].
Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844
[TBL] [Abstract][Full Text] [Related]
35. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
36. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
37. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of PRMT5 Attenuates Oxidative Stress-Induced Pyroptosis via Activation of the Nrf2/HO-1 Signal Pathway in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Diao C; Chen Z; Qiu T; Liu H; Yang Y; Liu X; Wu J; Wang L
Oxid Med Cell Longev; 2019; 2019():2345658. PubMed ID: 31885778
[TBL] [Abstract][Full Text] [Related]
39. PRMT5 inhibition promotes osteogenic differentiation of mesenchymal stromal cells and represses basal interferon stimulated gene expression.
Kota SK; Roening C; Patel N; Kota SB; Baron R
Bone; 2018 Dec; 117():37-46. PubMed ID: 30189247
[TBL] [Abstract][Full Text] [Related]
40. Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ; Wilson NR; Pemmaraju N
Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
